Published 2025-12-01
Keywords
- Chromium,
- diabetes,
- insulin signalling,
- transferrin
How to Cite
Copyright (c) 2025 Swami Vivekananda University Press

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Abstract
Chromium(III) has been proposed to have a dietary or pharmacological position in changing frame composition and enhancing signs and symptoms of insulin resistance, kind II diabetes, and related conditions even though the mode of action of Cr(III) at a molecular degree has didn’t be elucidated. This assessment info the cutting-edge reputation of research into Cr(III) supplementation. Clinical trials, meta-analyses and systematic critiques have didn’t show clinically widespread results from Cr(III) supplementation on frame composition or symptoms of insulin resistance and related conditions in people and livestock. despite the fact that new Cr(III) supplements hold to appear inside the clinical literature, research have did not elucidate the mechanism of chromium action at a molecular level. Conflicting results on a position of transferrin in Cr(III) transport and detoxing have appeared. Cr(III) supplementation cannot presently be endorsed in people or livestock. further studies are required to probe the mechanism of Cr(III) movement in growing insulin sensitivity and glucose uptake in rodent fashions of insulin resistance and diabetes, with unique attention being became to a ability position of transferrin in Cr(III) transport and cleansing.
DOI - https://doi.org/10.65525/SVUP.9788198471956.2025.55-63